Avacta Group (LON:AVCT – Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported GBX (4.23) EPS for the quarter, Digital Look Earnings reports. Avacta Group had a negative return on equity of 2,983.28% and a negative net margin of 34,584.96%.
Avacta Group Price Performance
AVCT traded up GBX 0.65 during midday trading on Wednesday, reaching GBX 72.65. 598,123 shares of the company’s stock were exchanged, compared to its average volume of 1,710,805. The company has a debt-to-equity ratio of 602.46, a current ratio of 0.89 and a quick ratio of 4.96. Avacta Group has a 1-year low of GBX 48 and a 1-year high of GBX 92. The stock has a market capitalization of £340.40 million, a PE ratio of -7.52 and a beta of 1.12. The business’s 50-day moving average price is GBX 69.58 and its 200 day moving average price is GBX 71.78.
Avacta Group Company Profile
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.
Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).
Read More
- Five stocks we like better than Avacta Group
- 3 Emerging Biotech Stocks With Significant Upside Potential
- Treasury Yields Haven’t Been This High Since 2007—3 ETFs to Watch
- 3 Healthcare Dividend Stocks Offering More Than Just Income
- AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
